← Shandong Yisheng Livestock & Poultry Breeding overview

Shandong Yisheng Livestock & Poultry Breeding vs CSPC Innovation Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Shandong Yisheng Livestock & Poultry Breeding Co Ltd (002458.CS)

Q3 20266 Jul – 23 Jul 2026

▲4

Yisheng profit surges 4,897% on broiler boom, record dividend

Hog price rally lifts livestock sector National average hog prices jumped 13% week-on-week to above 11 yuan per kilogram, with breeding sow capacity cuts continuing. This sector-wide rally pulled Yisheng shares up nearly 6% in a single session, as investors bet on a new livestock cycle lifting all animal farming stocks.
Explains the early-period sector rally that first moved Yisheng shares.
Half-year profit explodes on broiler volume and price gains Yisheng reported first-half net profit of 308 million yuan, up 4,897% year-on-year, on revenue up 28%. Parent-stock broiler breeders and commercial chicks both sold more at higher prices. This is the core driver: the white-feather broiler business is firing on all cylinders, proving the earnings power behind the stock.
The earnings surge is the single biggest fundamental driver of the stock.
Record mid-term dividend signals confidence The company proposed a cash dividend of 1.5 yuan per 10 shares, a total payout of 211 million yuan, potentially its largest-ever interim dividend. Paying out roughly two-thirds of profit shows management confidence in cash generation and gives income-focused investors a concrete reason to hold the stock.
Dividend policy directly affects shareholder returns and stock appeal.
Breeding pig business scales up fast Breeding pig sales hit 73,557 in the first half, up over 90% year-on-year, pushing Yisheng into the top tier of national breeding pig enterprises. This adds a second growth engine beyond broilers, diversifying revenue and reducing reliance on a single poultry cycle.
New business line broadens the growth story beyond broilers.

July 20266 Jul – 23 Jul 2026

▲4

Yisheng profit surges 4,897% on broiler boom, record dividend

Hog price rally lifts livestock sector National average hog prices jumped 13% week-on-week to above 11 yuan per kilogram, with breeding sow capacity cuts continuing. This sector-wide rally pulled Yisheng shares up nearly 6% in a single session, as investors bet on a new livestock cycle lifting all animal farming stocks.
Explains the early-period sector rally that first moved Yisheng shares.
Half-year profit explodes on broiler volume and price gains Yisheng reported first-half net profit of 308 million yuan, up 4,897% year-on-year, on revenue up 28%. Parent-stock broiler breeders and commercial chicks both sold more at higher prices. This is the core driver: the white-feather broiler business is firing on all cylinders, proving the earnings power behind the stock.
The earnings surge is the single biggest fundamental driver of the stock.
Record mid-term dividend signals confidence The company proposed a cash dividend of 1.5 yuan per 10 shares, a total payout of 211 million yuan, potentially its largest-ever interim dividend. Paying out roughly two-thirds of profit shows management confidence in cash generation and gives income-focused investors a concrete reason to hold the stock.
Dividend policy directly affects shareholder returns and stock appeal.
Breeding pig business scales up fast Breeding pig sales hit 73,557 in the first half, up over 90% year-on-year, pushing Yisheng into the top tier of national breeding pig enterprises. This adds a second growth engine beyond broilers, diversifying revenue and reducing reliance on a single poultry cycle.
New business line broadens the growth story beyond broilers.

Latest6 Jul – 23 Jul 2026

▲4

Yisheng profit surges 4,897% on broiler boom, record dividend

Hog price rally lifts livestock sector National average hog prices jumped 13% week-on-week to above 11 yuan per kilogram, with breeding sow capacity cuts continuing. This sector-wide rally pulled Yisheng shares up nearly 6% in a single session, as investors bet on a new livestock cycle lifting all animal farming stocks.
Explains the early-period sector rally that first moved Yisheng shares.
Half-year profit explodes on broiler volume and price gains Yisheng reported first-half net profit of 308 million yuan, up 4,897% year-on-year, on revenue up 28%. Parent-stock broiler breeders and commercial chicks both sold more at higher prices. This is the core driver: the white-feather broiler business is firing on all cylinders, proving the earnings power behind the stock.
The earnings surge is the single biggest fundamental driver of the stock.
Record mid-term dividend signals confidence The company proposed a cash dividend of 1.5 yuan per 10 shares, a total payout of 211 million yuan, potentially its largest-ever interim dividend. Paying out roughly two-thirds of profit shows management confidence in cash generation and gives income-focused investors a concrete reason to hold the stock.
Dividend policy directly affects shareholder returns and stock appeal.
Breeding pig business scales up fast Breeding pig sales hit 73,557 in the first half, up over 90% year-on-year, pushing Yisheng into the top tier of national breeding pig enterprises. This adds a second growth engine beyond broilers, diversifying revenue and reducing reliance on a single poultry cycle.
New business line broadens the growth story beyond broilers.

CSPC Innovation Pharmaceutical Co Ltd Class A (300765.CS)

Q3 202616 Jul – 14 Sep 2026

▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.
The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.
SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.
This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.
Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.
These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

August 202616 Jul – 14 Sep 2026

▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.
The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.
SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.
This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.
Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.
These regulatory and clinical steps expand the pipeline and signal more near-term product launches.

Latest16 Jul – 14 Sep 2026

▲3

CSPC Innovation Swings to Profit as Cancer Drug Pipeline Hits Key Milestones

Interim profit turnaround confirms commercial ramp CSPC Innovation reported a first-half net profit of 1.261 billion yuan, reversing a year-ago loss, with revenue up 208.7% to 3.24 billion yuan and a 76.7% gross margin. This shows the biopharma business is now generating real cash and earnings, which supports the stock's valuation.
The swing to profit is the clearest fundamental driver of the stock's value and confirms the business is no longer loss-making.
SYS6010 Phase III success and strong lung cancer data SYS6010 met its main goal in a Phase III lung cancer trial, and new data showed it combined with another drug shrank tumors in up to 82.4% of high-PD-L1 patients. These results raise the odds of approval and future sales, boosting investor confidence.
This is the most advanced pipeline asset with late-stage success, directly increasing the probability of a major new revenue stream.
Two new drug applications advance toward market A marketing application for a HER2 ADC for breast cancer was accepted, and a Phase III trial for a B7-H3 ADC in ovarian cancer began. Both move the company closer to adding new approved products, which would broaden future revenue.
These regulatory and clinical steps expand the pipeline and signal more near-term product launches.